Medical Device Autism Spectrum Disorder Therapeutics Market | Page 2

REPORT DESCRIPTION
Autism Spectrum Disorder Therapeutics Market – Overview
Autism Spectrum Disorder (ASD) is a neurodegenerative disorder, which is associated and often overlaps
with other conditions such as epilepsy, frequent infections, sleep disorders, anxiety, depression, and
gastrointestinal problems. ASD is only diagnosed by developmental and comprehensive tests. It can be
detected at eighteen months to two years of age. Drugs such as Aripiprazole, Risperidone, and Melatonin
are U.S. Food and Drug Administration (FDA) approved drugs that aid in the treatment of ASD.
Bumetanide and Balovaptan are the drugs that are under clinical trial and investigation to evaluate their
safety and efficacy for the treatment of ASD.
The global autism spectrum disorder therapeutics (ASD) therapeutics market size was valued at US$
2,169.3 million in 2018, and is expected to witness a CAGR of 6.8% over the forecast period (2018 –
2026).